Home » Newsletters » BioWorld Science

BioWorld Science

April 29, 2003

View Archived Issues

Targeted Genetics and Cystic Fibrosis Foundation Therapeutics collaborate on tgAAV-CF

NIH offers licenses to new chondropsin V-ATPase inhibitor

Effective back and leg pain alleviation reported with infliximab in sciatica

Donepezil plus conventional neuroleptics effective for psychotic symptoms in AD

Tadalafil confirmed to be effective and well tolerated in patients with erectile dysfunction

A potential new indication described for mycophenolate mofetil

Greater benefits found for sildenafil plus sertraline in premature ejaculation

Antitumor efficacy reported for a novel monoclonal antibody in advanced renal cell carcinoma

Highly potent Pfs inhibitors identified at Quorex as potential broad-spectrum antimicrobials

Testosterone gel restores physiological serum levels of testosterone in hypogonadal men

BMS researchers design novel chemokine CCR3 receptor modulators

SCI-induced bladder hyperreflexia improved by NK2 receptor antagonists

New cathepsin inhibitors with utility in osteoporosis therapy reported by Celera

New CXCR2 antagonists and their use in rheumatoid arthritis and COPD

Zeria researchers present new H+/K+-ATPase inhibitors

Novel 5-HT receptor modulators in early development at Pharmacia

Macrocyclic antibacterial agents prepared and tested at Bayer

Indole-based prostanoid DP receptor antagonists newly discovered at Ono

Merck scientists isolate a novel HIV integrase inhibitor from Cytospora cultures

Another series of alpha2/alpha3-selective GABA-A modulators reported by Merck

Celgene discusses progress during the first quarter

First-quarter highlights at Tularik

Nippon Boehringer Ingelheim and Sankyo intend to comarket Alesion

MedImmune postpones MEDI-507 trials in psoriasis

GenVec and NIAID to develop SARS vaccine

Search for SARS treatment at Medarex and MBL

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...